Journals / Nöropsikiyatri Arşivi / 2020 / Cilt: 57 - Sayı: 4

Efficacy and Tolerability of Interferon Gamma in Treatment of Friedreich’sAtaxia: Retrospective Study

Friedreich Ataksisi Tedavisinde İnterferon Gama Etkinliği ve Tolerabilitesi: Retrospektif Çalışma

Pages
270–273
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To the best of our knowledge, this is the first study conducted in our country to evaluate the effect of IFN gamma on this patient group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Friedreich’s Ataxia (FRDA) is the most common form of autosomal recessive ataxia.
📊
Key Findings & Data:The disease primarily results from a GAA trinucleotide repeat expansion within the FXN gene in up to 97% of patients.
💡
Conclusion & Impact:To the best of our knowledge, this is the first study conducted in our country to evaluate the effect of IFN gamma on this patient group.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Friedreich’s Ataxia (FRDA) is the most common form of autosomal recessive ataxia. The disease primarily results from a GAA trinucleotide repeat expansion within the FXN gene in up to 97% of patients. The clinical presentation begins approximately between the ages of 5 and 15. The major clinical findings of FRDA are progressive extremity and gait ataxia. Although it is known that the disease is caused by low levels of functional protein in the target tissues, there is no effective treatment available for this pathology. However, significant improvements have been achieved in the research into pharmacological treatments for FRDA in recent years. Interferon-gamma (IFN-γ) has been shown to induce frataxin production in many cell types. In this study, the clinical features, tolerability, and the prognosis of individuals with FRDA to whom IFN-γwas administered in a university hospital were evaluated retrospectively and the results were discussed. To the best of our knowledge, this is the first study conducted in our country to evaluate the effect of IFN gamma on this patient group.

Özet

Friedreich Ataksisi (FRDA) en yaygın otozomal resesif ataksidir. Hastalık,hastaların %97’sine yakınında FXN geninde GAA trinükleotid tekrarartışından kaynaklanır. Klinik prezentasyon yaklaşık 5 ile 15 yaşları arasındabaşlar. FRDA’nın başlıca klinik bulguları progresif ekstremite ve yürüyüşataksisidir. Hastalığın hedef dokulardaki düşük fonksiyonel proteindüzeylerinden kaynaklandığı bilinmesine rağmen, bu patoloji için etkilibir tedavi yoktur. Bununla birlikte, son yıllarda FRDA için farmakolojiktedavilerle ilgili araştırmalarda önemli gelişmeler sağlanmıştır. İnterferongama (IFN-γ)’nın birçok hücre tipinde frataksin üretimini indüklediğigösterilmiştir. Bu çalışmada bir üniversite hastanesinde IFN-γ uygulananFRDA’lı bireylerin klinik özellikleri, toleransı ve prognozu retrospektifolarak değerlendirilmiş ve sonuçlar tartışılmıştır. Bildiğimiz kadarıylabu çalışma ülkemizde IFN-γ’nın bu hasta grubu üzerindeki etkisinideğerlendirmek için yapılan ilk çalışmadır

🔖

Cite This Article

YETKİN, M. F., Gültekin, M. (2022). Efficacy and Tolerability of Interferon Gamma in Treatment of Friedreich’sAtaxia: Retrospective Study. Nöropsikiyatri Arşivi, Cilt: 57 - Sayı: 4, 270–273. https://ajindex.com/articles/584623

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Klockgether T. Ataxias. Parkinsonism Relat Disord 2007
  2. S391–S394. [Crossref] 2. Campuzano V, Montermini L, Molto MD, Pianese L, Cossée M, Cavalcanti F, Monros E, Rodius F, Duclos F, Monticelli A, Zara F, Canizares J, Koutnikova H, Bidichandani SI, Gellera C, Brice A, Trouillas P, De Michele G, Filla A, De Frutos R, Palau F, Patel PI, Di Donato S, Mandel JL, Cocozza S, Koenig M, Pandolfo M. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996
  3. 1423–1427. [Crossref] 3. Cossée M, Dürr A, Schmitt M, Dahl N, Trouillas P, Allinson P, Kostrzewa M, Nivelon-Chevallier A, Gustavson KH, Kohlschütter A, Mandel JL, Brice A, Koenig M, Cavalcanti F, Tammaro A, De Michele G, Filla A, Cocozza S, Labuda M, Montermini L, Poirier J, Pandolfo M. Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol 1999
  4. 200–206. [Crossref] 4. Harding A, Zilkha K. ‘Pseudo-dominant’ inheritance in Friedreich’s ataxia. J Med Genet 1981
  5. 285–287. [Crossref] 5. Boz PB, Koc F, Kocatürk Sel S, Güzel Aİ, Kasap H. Determination of Genotypic and Phenotypic Characteristics of Friedreich’s Ataxia and Autosomal Dominant Spinocerebellar Ataxia Types 1, 2, 3, and 6. Nöro Psikiyatri Arş 2016
  6. 115–119. [Crossref] 6. Boesch S, Nachbauer W, Mariotti C, Sacca F, Filla A, Klockgether T, Klopstock T, Schöls L, Jacobi H, Büchner B, vom Hagen JM, Nanetti L, Manicom K. Safety and tolerability of carbamylated erythropoietin in Friedreich’s ataxia. Mov Disord 2014
  7. 935–939. [Crossref] 7. Libri V, Yandim C, Athanasopoulos S, Loyse N, Natisvili T, Law PP, Chan PK, Mohammad T, Mauri M, Tam KT, Leiper J, Piper S, Ramesh A, Parkinson MH, Huson L, Giunti P, Festenstein R. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich’s ataxia: an exploratory, open-label, dose-escalation study. Lancet 2014
  8. 504–513. [Crossref] 8. Mariotti C, Nachbauer W, Panzeri M, Poewe W, Taroni F, Boesch S. Erythropoietin in F riedreich ataxia. J Neurochem 2013
  9. 80–87. [Crossref] 9. Pandolfo M, Arpa J, Delatycki MB, Le Quan Sang KH, Mariotti C, Munnich A, Sanz-Gallego I, Tai G, Tarnopolsky MA, Taroni F, Spino M, Tricta F. Deferiprone in F riedreich ataxia: A 6-Month randomized controlled trial. Ann Neurol 2014
  10. 509–521. [Crossref] 10. Aranca TV, Jones TM, Shaw JD, Staffetti JS, Ashizawa T, Kuo SH, Fogel BL, Wilmot GR, Perlman SL, Onyike CU, Ying SH, Zesiewicz TA. Emerging